ArticleBMC cancer2024

Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors.

Tirtha Mandal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.